DNA vaccine aims to train immune system against HPV-Linked cervical lesions
NCT ID NCT04131413
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 1 trial tests a DNA vaccine designed to target HPV16, a virus that can cause high-grade cervical lesions (CIN2/3). The vaccine is given by injection into the muscle followed by a mild electrical pulse to help cells take up the DNA. The study includes both HIV-negative and HIV-positive women with confirmed HPV16-positive lesions. The main goal is to see if the vaccine is safe and tolerable at different doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pNGVL4aCRTE6E7L2 HPV DNA vaccine
- What this could lead to
- If successful, this vaccine could offer a non-surgical treatment option for precancerous cervical lesions caused by HPV16.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. The vaccine may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21231, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States